abrdn Income Credit Strategies Fund vs Merck & Co., Inc. — how do they compare? abrdn Income Credit Strategies Fund trades at $5.1 (market cap $641.16M), while Merck & Co., Inc. trades at $133.42 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 501.9× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (18.2%). Which is the better fit depends on your goals.
| ACP | MRK | |
|---|---|---|
Market Cap | $641.16M | $321.77B |
Sector | Financials | Health |
52-Week High | $5.98 | $131.84 |
52-Week Low | $5.01 | $77.60 |
Dividend Yield | 18.2% | 2.61% |
Enterprise Value | — | $368.53B |
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.15 with a 1.38% daily gain, showing neutral technical signals with bearish moving averages. The stock maintains strong profitability with a 95.31% net income margin and attractive valuation at 7.74 P/E ratio. Recent dividend declarations of $0.08 per share demonstrate income focus, though revenue declined from $79M in 2024 to $42M in 2025 before projected recovery to $85M in 2026.
ACP presents a mixed outlook with sustainable dividends and undervalued metrics offset by revenue volatility and high leverage concerns. The 17% distribution rate faces sustainability questions with only 49% supported by net investment income. Investors should weigh the attractive yield against credit spread risks and global exposure in this high-beta closed-end fund.
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Trailing returns across standard periods
Latest headlines on both assets
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →